Please assess the completion status of the following clinical trial:

Trial Title: Sequential Bacillus Calmette-Guérin (BCG) and Electromotive Mitomycin-C Versus Bacillus Calmette-Guérin (BCG) Alone for High Risk Superficial Bladder Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adequate bone-marrow reserve (ie, white-blood-cell count ≥4000 x106 cells/L and platelet count ≥120 x 109/L)~* normal renal function (ie, serum creatinine ≤123•76 μmol/L)~* normal liver function (ie, serum glutamic-oxaloacetic transaminase ≤42 U/L, serum glutamic-pyruvic transaminase ≤48 U/L, and total bilirubin ≤22•23 μmol/L)~* Karnofsky performance status between 50 and 100.~Exclusion Criteria:~* previous treatment with BCG or electromotive mitomycin~* treatment with any other intravesical cytostatic agent within the past 6 months~* concomitant urothelial tumours of the upper urinary tract;~* previous muscle-invasive (ie, stage T2 or higher) transitional-cell - carcinoma of the bladder~* bladder capacity less than 2 L~* untreated urinary-tract infection~* severe systemic infection (ie, sepsis)~* urethral strictures that would prevent endoscopic procedures and repeated catheterisation~* disease of upper urinary tract (eg, vesicoureteral reflux or urinary-tract stones) that would make multiple transurethral procedures a risk~* previous radiotherapy to the pelvis~* other concurrent chemotherapy~* treatment with radiotherapy-response or biological-response modifiers;~* history of tuberculosis~* other malignant diseases within 5 years of trial registration (except for basal-cell carcinoma)~* pregnancy or nursing~* psychological, familial, sociological, or geographical factors that would preclude study participation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Intravesical BCG alone (Type: ACTIVE_COMPARATOR): None
- Intravesical sequential BCG and EMDA MMC (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).